Exchange: NASDAQ·Updated 05:27 PM EDT
DXCM logo

DXCMDexcom Inc

$73.02
$1.04
(1.40%)
Today
Closed $73.02
$0.00
(0.00%)
After Hours
EarningsJul 30
Mkt Cap$28.58B
Vol4.16M
News
all
press releases
Dexcom Schedules Second Quarter 2026 Earnings Release and Conference Call for July 30, 2026 at 4:30 p.m. Eastern Time
DexCom, Inc. (NASDAQ:DXCM) today announced that it plans to release its second quarter 2026 financial results after market close on Thursday, July 30, 2026. Management will hold a conference call to review the company's second quarter 2026 performance starting at 4:30 p.m. (Eastern Time) on the...
Business Wire
News Placeholder
More News
News Placeholder
Here's Why DexCom (DXCM) is a Strong Growth Stock
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Zacks
News Placeholder
Here's Why You Should Retain DexCom Stock in Your Portfolio for Now
DXCM's expanding CGM reach, G7 15 Day rollout and international momentum support growth, but can reimbursement and cost risks temper the outlook?
Zacks
News Placeholder
Did DexCom, Inc. Insiders Breach their Fiduciary Duties to Shareholders?
Did DexCom, Inc. Insiders Breach their Fiduciary Duties to Shareholders? Did DexCom, Inc. Insiders Breach their Fiduciary Duties to Shareholders? PR Newswire NEW YORK, July 3, 2026 Shareholders are encouraged to contact the firm to discuss their rights and options at no cost or obligation. We would...
PR Newswire
News Placeholder
DexCom, Inc. (DXCM) Further Advances Vision of Glucose Biosensing for All
DexCom, Inc. (DXCM) Further Advances Vision of Glucose Biosensing for All...
Yahoo! Finance: News
News Placeholder
Abbott vs. DexCom: Which CGM Stock Is the Better Option Right Now?
DXCM outpaces Abbott with expanding CGM access, new product launches and broader coverage, making it the stronger stock to watch now.
Zacks
News Placeholder
DexCom to Roll Out Reimagined Stelo App With Global Expansion Plans
DXCM's redesigned Stelo app is set for a July U.S. rollout, with international expansion and pediatric clearance broadening its glucose insights push.
Zacks
News Placeholder
Dexcom Further Advances Vision of Glucose Biosensing for All
DexCom, Inc. (NASDAQ: DXCM), the global leader in glucose biosensing, today announced at Aspen Ideas: Health a series of milestones that advance its vision of making glucose biosensing more accessible. Notably, the company announced pediatric clearance for the Stelo Glucose Biosensor and the launch...
Business Wire
News Placeholder
Here's How Much You Would Have Made Owning DexCom Stock In The Last 20 Years
read more...
Benzinga
News Placeholder
DXCM Receives FDA Clearance for Stelo OTC CGM System for Children
DexCom's FDA-cleared Stelo OTC glucose biosensor now covers children aged above 2 years not using insulin, expanding access to smartphone-linked CGM insights.
Zacks
<
1
2
...
>

Advertisement|Remove ads.